Risk Factors and Mechanisms of Cardiotoxicity in Hsct Publisher



Janbabai G¹ ; Vaezi M² ; Khodaamorzideh D³ ; Salehi MM³ Show Affiliations
Source: Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation Published:2024

Abstract

Cardiotoxicity Cardiotoxicity in individuals undergoing HSCT is influenced by a variety of factors. To begin, it can be said that any previous cardiotoxic therapies, such as chest radiation Chest radiation and anthracyclines Anthracyclines, raise the risk of cardiotoxicity Cardiotoxicity in the future. Furthermore, the development of comorbid disorders such as dyslipidemia (DLP), diabetes mellitus Diabetes Mellitus (DM), or hypertension Hypertension (HTN) as a result of HSCT Hematopoietic Stem Cell Transplantation (HSCT) or GVHD is Graft Versus Host Disease (GVHD) accompanied by an increased risk of cardiovascular disease Cardiovascular disease in the long run (Tuzovic et al. in Curr Oncol Rep 21(3):28, 2019). In addition, the effects of dimethyl sulfoxide, which is employed to preserve stem cells, are likely to have a role in cardiac events (Cox et al. JunCell Tissue Bank 13:203-215, 2012). Other HSCT-related comorbidities, such as sepsis (Ghafoor in Critical care of the pediatric immunocompromised hematology/oncology patient. Springer, Cham, pp. 211-235, 2009), thrombotic microangiopathy (Pfeiffer et al. in Bone Marrow Transp 52:630-633, 2017; Dandoy et al. in Biol Blood Marrow Transplant 19:1546-1556, 2013; Jodele et al. in Transfus Apher Sci 54:181-190, 2016), and hepatic veno-occlusive disease (Ovchinsky et al. in Biol Blood Marrow Transp 24:207-218, 2016) (Table 1) might also cause cardiac problems. © Springer Nature Switzerland AG 2024. All rights reserved.